Esperion Q4 rev $168.4M (+144% Y/Y); FY25 rev $403.1M; Q4 net income $61.8M; acquires Corstasis

Esperion Therapeutics, Inc.

U.S. net product revenue Q4 $43.7M (+38% Y/Y); FY25 $159.6M (+38% Y/Y).
Collaboration revenue Q4 $124.7M (includes $90M Otsuka milestone); FY25 $243.6M (+12% Y/Y).
Q4 net income $61.8M ($0.26 basic EPS vs loss $0.11 in Q4 2024); FY25 net loss $22.7M narrowed from $51.7M.
Agreed to acquire Corstasis Therapeutics (Enbumyst nasal spray for CHF edema); targets $4B U.S. market.
Patent settlements restrict generic entry until April 2040; FY26 opex guidance $225-255M (incl ~$15M non-cash).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Esperion Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $403.1 Million.

Period: the full year ended December 31, 2025
Revenue: $403.1 Million
Result: reported results

Exact text from the filing

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Esperion Therapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $168.4 Million.

Period: the fourth quarter ended December 31, 2025
Revenue: $168.4 Million
Result: reported results

Exact text from the filing

– Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million –

View on SEC.gov

Browse all earnings releases →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-016230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.